Business Description
Bausch & Lomb Corp
NAICS : 333314
SIC : 3912
ISIN : CA0717051076
Description
Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.06 | |||||
| Equity-to-Asset | 0.49 | |||||
| Debt-to-Equity | 0.71 | |||||
| Debt-to-EBITDA | 8.75 | |||||
| Interest Coverage | 0.51 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 0.91 | |||||
| Beneish M-Score | -2.55 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8.3 | |||||
| 3-Year EBITDA Growth Rate | -10.7 | |||||
| 3-Year EPS without NRI Growth Rate | -89.2 | |||||
| 3-Year Book Growth Rate | -10.3 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 8.55 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.67 | |||||
| 9-Day RSI | 52.45 | |||||
| 14-Day RSI | 51.63 | |||||
| 6-1 Month Momentum % | 1.35 | |||||
| 12-1 Month Momentum % | -9.09 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.65 | |||||
| Quick Ratio | 1.01 | |||||
| Cash Ratio | 0.17 | |||||
| Days Inventory | 191.18 | |||||
| Days Sales Outstanding | 69.91 | |||||
| Days Payable | 85.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.1 | |||||
| Shareholder Yield % | -36.13 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 60.84 | |||||
| Operating Margin % | 4.26 | |||||
| Net Margin % | -10.17 | |||||
| FCF Margin % | -3.03 | |||||
| ROE % | -6.79 | |||||
| ROA % | -3.56 | |||||
| ROIC % | 2.86 | |||||
| 3-Year ROIIC % | 15.87 | |||||
| ROC (Joel Greenblatt) % | 5.52 | |||||
| ROCE % | 1.04 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 18.35 | |||||
| PS Ratio | 1.27 | |||||
| PB Ratio | 0.87 | |||||
| Price-to-Operating-Cash-Flow | 48.06 | |||||
| EV-to-EBIT | 85.33 | |||||
| EV-to-Forward-EBIT | 30.56 | |||||
| EV-to-EBITDA | 18.76 | |||||
| EV-to-Forward-EBITDA | 14.12 | |||||
| EV-to-Revenue | 2.24 | |||||
| EV-to-Forward-Revenue | 1.48 | |||||
| EV-to-FCF | -73.35 | |||||
| Earnings Yield (Greenblatt) % | 1.17 | |||||
| FCF Yield % | -2.4 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers